Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes

Journal of Medical Virology

Volumn 81, Issue 6, 2009, Pages 996-1001

  Selabe, S Gloria ^a,c   Song, Ernest ^b   Burnett, Rosemary J ^a   Mphahlele, M Jeffrey ^a  

^a UNIVERSITY OF LIMPOPO   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

Author keywords

Basal core promoter; HBV genotypes; Hepatitis B virus; Lamivudine resistance; Pre core; South Africa

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; ANTIVIRUS AGENT; VIRUS PROTEIN;

ADULT; AGED; ANALYZER; ARTICLE; ASSAY; CLINICAL ARTICLE; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENETICS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; POPULATION; PROMOTER REGION; RELAPSE; RETROSPECTIVE STUDY; SAMPLE; SOUTH AFRICA; TREATMENT FAILURE; VIRUS DETECTION; VIRUS MUTANT; VIRUS STRAIN; ANTIVIRAL RESISTANCE; CLASSIFICATION; DNA SEQUENCE; GENETIC POLYMORPHISM; ISOLATION AND PURIFICATION; MIDDLE AGED; MISSENSE MUTATION; POINT MUTATION; VIROLOGY;

HEPATITIS B VIRUS;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; POINT MUTATION; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA; VIRAL PROTEINS; YOUNG ADULT;

EID: 66449109836     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21479     Document Type: Article

References (42)

1. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2003. The influence of hepatitis B virus genotypes on the development of lamivudine-resistance during long-term treatment. J Hepatol 38:315-321. (Pubitemid 36286544)
2. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677. (Pubitemid 28264693)
3. Alter MJ. 2003. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 39:S64-S69. (Pubitemid 37222649)
4. Carman WF, Thursz M, Hadziyannis S, McIntyre G, Colman K, Gioustoz A, Fattovich G, Alberti A, Thomas HC. 1995. Hepatitis B e antigen negative chronic active hepatitis: Hepatitis B virus core mutations occur predominantly in known antigenic determinants. J Viral Hepat 2:77-84.
5. Chen CH, Lee CM, Lu SN, Changchien CS, Wang JC, Wang JH, Hung CH, Hu TH. 2006. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with andwithout HBeAg clearance in lamivudine therapy. J Hepatol 44:76-82. (Pubitemid 41772519)
6. Cho SW, Hahm KB, Kim JH. 2000. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 32:1163-1169.
7. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263. (Pubitemid 29489740)
8. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′- dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 88:8495-8499. (Pubitemid 21915383)
9. Gutpreund KS, Williams M, George R, Bain VS, Ma NM, Yoshida EM, Villeneuve JP, Fischer KP, Tyrrel DL. 2000. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 33:469-475. (Pubitemid 30663385)
10. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. 2000. Efficacy of long-term lamivudine monotherapy in patients with hepatitis Be antigen-negative chronic hepatitis B. Hepatology 32:847-851.
11. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C, Jones EA. 1988. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 95:1318-1325. (Pubitemid 18256902)
12. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW, HBV, 99-01 Study Group, Rotterdam Foundation for Liver Research. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 365:123-129.
13. Kagawa T, Watanabe N, Kanouda H, Takayama I, Shiba T, Kanai T, Kawazoe K, Takashimizu S, Kumaki N, Shimamura K, Matsuzaki S, Mine T. 2004. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. World J Gastroenterol 10: 1686-1687. (Pubitemid 38786959)
14. Kao JH, Chen PJ, Lai MY, Chen DS. 2003. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124:327-334. (Pubitemid 36169249)
15. Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. 2005. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantuspeaking sub-saharan Africans. J Med Virol 75: 513-521. (Pubitemid 40293518)
16. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. 2001. Fatal submassive hepatic necrosis associated with tyrosine-methionine- aspartateaspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 33:403-405. (Pubitemid 32664850)
17. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA, Telbivudine Phase II Investigator Group. 2005. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129:528-536. (Pubitemid 41096641)
18. Liaw YF, Chien RN, Yeh CT. 2004. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 9:257-262. (Pubitemid 38560218)
19. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. 2002. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 51:597-599.
20. Lin CL, Liao LY, Wang CS, Chen PJ, Lai MY, Chen DS, Kao JH. 2004. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. Liver Int 24:9-15. (Pubitemid 38351208)
21. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M, Andreone P. 2000. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 32:1145-1153.
22. Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases. 2001. Chronic hepatitis B. Hepatology 34:1225-1241.
23. MelegariM, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633. (Pubitemid 28081083)
24. Miyakawa Y, Mizokami M. 2003. Classifying hepatitis B virus genotypes. Intervirology 46:329-338. (Pubitemid 38037030)
25. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. 2006. High risk of occult hepatitis B virus infection in HIV positive patients from South Africa. J Clin Virol 35:14-20. (Pubitemid 43020947)
26. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. 1998. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 177:1382-1385. (Pubitemid 28194283)
27. Norder H, Courouce AM, Magnius LO. 1994. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 198:489-503. (Pubitemid 124019485)
28. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. 1990. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 64:1298-1303. (Pubitemid 20087771)
29. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. 1994. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 68:8102-8110. (Pubitemid 24984172)
30. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E. 2004. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126:81-90. (Pubitemid 38040726)
31. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. 2007. Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol 79:1650-1654. (Pubitemid 47479881)
32. Shaw T, Locarnini S. 2004. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2:853-871. (Pubitemid 39591919)
33. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. 2000. A new genotype of hepatitis B virus: Complete genome and phylogenetic relatedness. J Gen Virol 81:67-74. (Pubitemid 30047907)
34. Suzuki F, Suzuki Y, Tsubota A, Akuta N, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2002. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 37:824-830. (Pubitemid 35404222)
35. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. 2004. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 78:8524-8535. (Pubitemid 39025118)
36. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF, Lamivudine Precore Mutant Study Group. 1999. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29:889-896. (Pubitemid 29109606)
37. Thakur V, Sarin SK, Rehman S, Guptan RC, Kazim SN, Kumar S. 2005. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol 24:12-15. (Pubitemid 40379920)
38. Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, Chen RY, Demediuk B, ShawG, Bell SJ, Watson KJ, Locarnini SA, Desmond PV. 2007. Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factors. J Gastroenterol Hepatol 22:1078-1085. (Pubitemid 47019852)
39. vanBommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, Wiedenmann B, Berg T. 2004. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40:1421-1425.
40. Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. 2002. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 37:366-369. (Pubitemid 34194826)
41. Yuen MF, Tanaka Y, Lai CL. 2003. Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. Intervirology 46:373-376. (Pubitemid 38037037)
42. Zollner B, Petersen J, Puchhammer-Stockl E, Kletzmayr J, Sterneck M, Fischer L, Schroter M, Laufs R, Feucht HH. 2004. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 39:42-50. (Pubitemid 38461465)